Peregrine Pharmaceuticals Inc. has formed a research collaboration with the National Comprehensive Cancer Network (NCCN) to expand the company’s ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN is a not-for-profit alliance of 26 of the world’s leading cancer centers. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate com...